TNFRSF17, also known as B-cell maturation antigen (BCMA), plays a critical role in the survival and differentiation of plasma cells and has emerged as a promising therapeutic target for multiple myeloma and other plasma cell disorders (61–74). This evidence concerns the gene TNFRSF17 and plasma cell myeloma.